Eleftha 440 mg Injection

Eleftha 440 mg Injection contains trastuzumab 440 mg, a targeted monoclonal antibody used in cancer treatment. It is mainly used for HER2-positive breast cancer and certain HER2-positive stomach cancers. The medicine is administered by intravenous infusion under the supervision of a qualified healthcare professional.

BUY NOW

Trastuzumab works by binding to the HER2 protein on cancer cells and blocking signals that promote their growth. It may be used alone or together with chemotherapy or other cancer treatments according to the patient’s clinical condition. Regular monitoring is important because treatment can cause infusion-related reactions and may affect heart function in some patients. The treatment schedule and duration are determined by the oncologist based on the cancer type, HER2 status, and response to therapy.

Technical Specification

Specification Details
Active Ingredient Trastuzumab
Strength 440 mg
Dosage Form Lyophilized Powder for Injection
Route of Administration Intravenous Infusion
Pack Size 1 Vial
Manufacturer Intas Pharmaceuticals Ltd

Product Also Known As

Eleftha 440mg Injection, Eleftha 440 mg Vial, Eleftha 440 Injection, Trastuzumab 440mg Injection, Trastuzumab 440 mg Injection, Trastuzumab 440mg Vial, HER2 Targeted Therapy Injection